Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 207, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112670
Keywords
Prodrug; Anticancer chemotherapy; Reactive oxygen species; Boronic acids and esters
Categories
Funding
- Ministere de l'Education Nationale de la Recherche et de la Technologie
- Ligue Nationale Contre le Cancer (comite de l'Essonne)
- Fondation ARC pour la recherche sur le cancer
Ask authors/readers for more resources
Boronic acid (and ester) prodrugs targeting the overexpressed level of reactive oxygen species within tumor microenvironment represent a promising area for the discovery of new selective anticancer chemotherapy. This strategy that emerged only ten years ago is exponentially growing and could demonstrate its clinical usefulness in the near future. Herein, the previously described small-molecule and macromolecular anticancer prodrugs activated by carbon-boron oxidation are gathered. This review reports on the most interesting derivatives mentioned in the literature based on the in vitro and in vivo activity when available. Eventually, the pharmacological applicability of this strategy is discussed, in particular, the kinetic aspect of the prodrug oxidation and the selectivity of this reaction towards certain ROS from the tumor microenvironment are specified. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available